Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide oral liquid in young children with autism spectrum disorder
NL-OMON45966Phase 3Withdrawn
- Sponsor
- Servier
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Bumetanide double-blind arm with Placebo double-blind arm (2 arms). Primary endpoint: Change from baseline to month 6 in Childhood Autism Rating Scale, Second Edition total raw score. Planned start Jun 2018; status: withdrawn.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NL-OMON45966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45966.